Price Alert

Repare Therapeutics Inc. (RPTX)

NASDAQ: RPTX · Real-Time Price · USD

1.74

0.05 (2.96%)

At close: Sep 29, 2025, 3:59 PM

1.73

-0.57%

After-hours: Sep 29, 2025, 05:08 PM EDT

2.96% (1D)

Bid	1.65
Market Cap	74.75M
Revenue (ttm)	53.73M
Net Income (ttm)	-109.86M
EPS (ttm)	-2.58
PE Ratio (ttm)	-0.67
Forward PE	-1.88
Analyst	Buy
Dividends	n/a

Ask	1.79
Volume	118,560
Avg. Volume (20D)	287,426
Open	1.69
Previous Close	1.69
Day's Range	1.67 - 1.74
52-Week Range	0.89 - 4.07
Beta	0.93
Ex-Dividend Date	n/a

About RPTX

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol RPTX

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for RPTX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Repare Therapeutics Inc. is scheduled to release its earnings on Nov 6, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

2 months ago

-8.92%

Repare Therapeutics shares are trading higher afte... Unlock content with Pro Subscription

9 months ago

-55.42%

Repare Therapeutics shares are trading lower after Stifel cut its price target on the stock from $9 to $4.

News

1 month ago · zacks.com

Repare Therapeutics Inc. (RPTX) Reports Q2 Loss, Misses Revenue Estimates

Repare Therapeutics Inc. (RPTX) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to a loss of $0.82 per share a year ago.

1 month ago · fool.com

Repare (RPTX) Q2 Loss Narrows 52%

1 month ago · businesswire.com

Repare Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, today reported financial results for the...

2 months ago · businesswire.com

Repare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced it has entered into an e...